不同治疗方案对鼻、鼻型NK/T细胞淋巴瘤疗效分析

目的：探讨鼻、鼻型NK/T细胞淋巴瘤的临床特征、治疗方法和预后。方法：收集自2004年1月-2010年1月在我院住院治疗的29例鼻、鼻型NK/T细胞淋巴瘤患者临床资料,分析其临床特点、治疗方案及预后。结果：治疗分CHOP方案组及L-ASP组,总有效率分别为56.3%和75.9%（P=0.045）。两组5年OS率和DFS率分别为43.75%、61.54%（P=0.038）及18.8%、46.15%（P=0.009）,具有统计学意义。难治组7例经VDLP方案补救化疗后总有效率为71.3%。B组症状、临床分期及KPS评分可能对患者的生存产生影响。结论：对于临床早期的鼻、鼻腔NK/T细胞淋巴瘤患者,初治时可以选择CHOP方案治疗,而中、晚期病例及CHOP方案治疗无效的病例,选择以左旋门冬酰胺酶为主的联合化疗结合放疗综合治疗可取得较好疗效。

Analysis of different treatment of nasal and nasal type NK/T-cell lymphoma

Objective：To explore the cilinical chamcteristics,prognostic factors,and treatment outcome of patients with nasal and nasal type NK/T-cell lymphoma.Methods： The cilinical data of 29 patients with nasal and nasal type NK / T-cell lymphoma who were followed up in our hospital from 2004 to 2010 were analyzed.Results： All 29 patients entered into our study.16 and 13 case in group CHOP,L-ASP respectively,the overall responese rates were 56.3% and 75.9% respectively（P=0.045）.The 5-year OS rates and DFS rates were 43.75% VS 61.54%（P=0.038） and 18.8% VS 46.15%（P=0.009） respectively,There was difference in overall responese rates,OS rate and DFS rate between two regimens.The overall responese rate of 7 refractory patients treated by salvage therapy VDLP was 71.3%,B symptoms,clinical stage and KPS grade might affect the survival of patients.Conclusion： Patients with nasal and nasal type NK / T-cell lymphoma can be treated by CHOP regimen and local radiotherapy.The patient at stage Ⅲ and Ⅳ or refractory patient can be treated by the regimen based on L-ASP chemotherapy with a rather good effect.